本页面由Tiger Trade Technology Pte. Ltd.提供服务

Verve Therapeutics

11.13
0.0000
成交量:- -
成交额:1.15亿
市值:9.94亿
市盈率:-5.30
高:11.13
开:11.13
低:11.13
收:11.13
52周最高:11.41
52周最低:2.86
股本:8,932.10万
流通股本:6,549.51万
量比:- -
换手率:- -
股息:- -
股息率:- -
每股收益(TTM):-2.1013
每股收益(LYR):-2.3454
净资产收益率:-34.26%
总资产收益率:-19.35%
市净率:2.10
市盈率(LYR):-4.75

数据加载中...

2025/07/25

重要事件披露

Form 8-K - Current report
2025/07/25

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/25

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/25

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/25

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/25

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/25

交易所摘牌声明

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2025/07/15

重要事件披露

Form 8-K - Current report
2025/06/17

重要事件披露

Form 8-K - Current report
2025/06/10

重要事件披露

Form 8-K - Current report
2025/05/14

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/05/14

重要事件披露

Form 8-K - Current report
2025/04/14

重要事件披露

Form 8-K - Current report
2025/02/27

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/02/27

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/02/27

重要事件披露

Form 8-K - Current report
2024/11/18

超过5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/11/05

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/11/05

重要事件披露

Form 8-K - Current report
2024/10/16

超过5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors